Literature DB >> 11306706

Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha.

E Hur1, K Y Chang, E Lee, S K Lee, H Park.   

Abstract

Under low oxygen tension, cells increase the transcription of specific genes that are involved in angiogenesis, erythropoiesis, and glycolysis. Hypoxia-induced gene expression primarily depends on the stabilization of the alpha-subunit of hypoxia-inducible factor-1 (HIF-1alpha), which acts as a heterodimeric trans-activator. Our results indicate that stabilization of HIF-1alpha protein by treatment of proteasome inhibitors, is not sufficient for hypoxia-induced gene activation, and an additional hypoxia-dependent modification is necessary for gene expression by HIF-1alpha. Here, we demonstrate that mitogen-activated protein kinase kinase-1 (MEK-1) inhibitor PD98059 does not change either the stabilization or DNA binding ability of HIF-1alpha but it inhibits the trans-activation ability of HIF-1alpha, thereby it reduces the hypoxia-induced transcription of both an endogenous target gene and a hypoxia-responsive reporter gene. We found that hypoxia induced p42/p44 mitogen-activated protein kinases (MAPKs) that are target protein kinases of MEK-1, and that expression of dominant-negative p42 and p44 MAPK mutants reduced HIF-1-dependent transcription of the hypoxia-responsive reporter gene. Our results are the first to identify that hypoxia-induced trans-activation ability of HIF-1alpha is regulated by different mechanisms than its stabilization and DNA binding, and that these processes can be experimentally dissociated. MEK-1/p42/p44 MAPK regulates the trans-activation, but not the stabilization or DNA binding ability, of HIF-1alpha.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306706     DOI: 10.1124/mol.59.5.1216

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

Review 1.  Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.

Authors:  Francisco Javier Rodríguez-Jiménez; Victoria Moreno-Manzano
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

Review 2.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Authors:  Balveen Kaur; Fatima W Khwaja; Eric A Severson; Shannon L Matheny; Daniel J Brat; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

3.  Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

Authors:  Christina D Befani; Panagiotis J Vlachostergios; Eleana Hatzidaki; Anna Patrikidou; Sophia Bonanou; George Simos; Christos N Papandreou; Panagiotis Liakos
Journal:  J Mol Med (Berl)       Date:  2011-09-10       Impact factor: 4.599

4.  Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia.

Authors:  Caroline Fradette; Patrick du Souich
Journal:  Br J Pharmacol       Date:  2003-10-14       Impact factor: 8.739

5.  TNFalpha induces HIF-1alpha expression through activation of IKKbeta.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Weiya Xia; Yongkun Wei; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2009-09-17       Impact factor: 3.575

Review 6.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

7.  Antimetastatic activity of MONCPT in preclinical melanoma mice model.

Authors:  Xiao-Chun Yang; Chong-Xing Tu; Pei-Hua Luo; Hong Zhu; Di-Feng Zhu; Hong-Hai Wu; Xing-Lu Zhou; Wei Lu; Qiao-Jun He; Bo Yang
Journal:  Invest New Drugs       Date:  2009-09-30       Impact factor: 3.850

8.  Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone.

Authors:  Hena Alam; Jennifer Weck; Evelyn Maizels; Youngkyu Park; Eun Jig Lee; Margaret Ashcroft; Mary Hunzicker-Dunn
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

Review 9.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).

Authors:  Dale G Nagle; Yu-Dong Zhou
Journal:  Curr Drug Targets       Date:  2006-03       Impact factor: 3.465

10.  Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.

Authors:  Archana Bommi-Reddy; Ingrid Almeciga; Jacqueline Sawyer; Christoph Geisen; Wenliang Li; Ed Harlow; William G Kaelin; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.